Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
The innate immune system serves as the body's specialized armed forces division, comprised of a host of defense mechanisms used to battle bacterial infections. Among the system's warriors are white blood cells including the specialized macrophages, which maintain constant surveillance for foreign intruders or pathogens, functioning as the body's first line of defense, poised to attack at barrier sites including the skin, lungs and intestines.
A UAlberta team has discovered that a protein that plays a critical role in metabolism, the process by which the cell generates energy from foods, is important for the development of pulmonary hypertension, a deadly disease.
medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests.
For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects.
Supraventricular arrhythmias are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension, a study shows.
Doppler echocardiography has good accuracy relative to right heart catheterisation for detecting pulmonary hypertension, shows a large study.
An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA.
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago.
A little white pill may help scientists learn why patients with cystic fibrosis have less exercise capacity than their peers, even if their lungs are relatively healthy.
The fact that mechanical heart valves increase risks during and after pregnancy, has been confirmed by data from the ROPAC registry presented for the first time today in an ESC Congress Hot Line session by Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall of the registry's executive committee.
The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines.
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs.
Patients with pulmonary hypertension have reduced right ventricular strain and more dyssynchronous ventricles than healthy individuals, show results of a three-dimensional speckle tracking study.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.
Oxygen uptake efficiency plateau, measured during the cardiopulmonary exercise test, offers a novel method for evaluating gas exchange abnormalities in patients with idiopathic pulmonary hypertension, Chinese researchers report.
An updated CHEST guideline for treating pulmonary arterial hypertension provides some evidence-based recommendations but also highlights many evidence gaps.
When a large blood clot was discovered attached to the end of a catheter inside the right atrial chamber of a patient's heart, doctors faced a daunting challenge.
RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.
A first-of-its-kind yoga exercise program has been developed by Henry Ford Hospital for patients living with pulmonary hypertension, a chronic lung disease that afflicts women at least two times more than men.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.